Summary NR 546 Antipsychotics Table

Iloperidne Target symptoms: Schizophrenia, schizophrenia maintenance, acute mania/mixed mania, other psychotic disorders, bipolar maintenance, bipolar depression, treatment-resistant depression, behavioral disturbances in dementia, children, and adolescents, disorders associated with problems with impulse control, PTSD. Positive and negative symptoms of psychosis, cognitive symptoms, unstable mood, aggressive symptoms. Potency: Atypical 2nd general antipsychotic Neurotransmitter(s) affected: Blocks dopamine 2 receptors, reducing positive symptoms of psychosis and stabilizing affective symptoms, blocks serotonin 2 A receptors, causing enhancement of dopamine release in certain brain regions and thus reducing motor side effects and possibly improving cognitive and affective symptoms, blockage of central alpha 1 adrenergic receptor may contribute to low potential for drug-induced parkinsonism Half-life: 18-33 hours Metabolism: CYP2D6, CYP3A4 Orthostatic hypotension  Sedation, dizziness, fatigue Dry mouth, nasal congestion  Weight gain Risk for diabetes, dyslipidemia Tachycardia  Tardive dyskinesia  Irreversible involuntary dyskinetic movements Hyperglycemia Neuroleptic malignant syndrome